Genmab A/S (Genmab A/S) Additional Paid-In Capital : $1,823 Mil(As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Additional Paid-In Capital?

Genmab A/S's quarterly additional paid-in capital declined from Jun. 2023 ($1,806 Mil) to Sep. 2023 ($1,782 Mil) but then increased from Sep. 2023 ($1,782 Mil) to Dec. 2023 ($1,823 Mil).

Genmab A/S's annual additional paid-in capital declined from Dec. 2021 ($1,828 Mil) to Dec. 2022 ($1,753 Mil) but then increased from Dec. 2022 ($1,753 Mil) to Dec. 2023 ($1,823 Mil).

Genmab A/S Additional Paid-In Capital Historical Data

The historical data trend for Genmab A/S's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Additional Paid-In Capital Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,748.50

1,944.93

1,827.84

1,752.70

1,823.17

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,752.70	1,775.12	1,806.20	1,781.99	1,823.17

Genmab A/S Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Genmab A/S Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.